The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Cardiac comorbidities in lung cancer: bridging the evidence gap in clinical practice
Gerard M Walls, MB, MRCP, MSc, FRCR, Queens University, Belfast, UK, discusses the issue of patients with significant cardiac comorbidities being excluded from clinical trials, creating an evidence gap in treatment decisions. Dr Walls highlights the need to adapt clinical trials to include patients with chronic cardiac problems and emphasizes the importance of interdisciplinary collaboration with cardiology experts to make informed treatment decisions for these patients. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
